A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma.

Berenson, James R

A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma. [electronic resource] - Clinical lymphoma Sep 2004 - 130-4 p. digital

Publication Type: Clinical Trial; Journal Article

1526-9655

10.3816/clm.2004.n.020 doi


Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Arsenic Trioxide
Arsenicals--administration & dosage
Ascorbic Acid--administration & dosage
Disease Progression
Drug Resistance, Neoplasm
Humans
Melphalan--administration & dosage
Middle Aged
Multiple Myeloma--drug therapy
Oxides--administration & dosage
Prospective Studies
Recurrence
Time Factors
Treatment Outcome